Aims & Scope
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings and reviews solicited by the editor on the subject of the identification of markers associated with the prevention, detection, diagnosis, and treatment of cancer whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomic, cellular and morphologic, and genetic risk factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these risk factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation, will be accepted. Data science, artificial intelligence, radiomics, and other molecular approaches, such as bulk and single cell genomic sequence analyses for biomarkers discovery, development, and validation in reference to cancer prevention and treatment, will also be accepted.
Sudhir Srivastava, PhD, MPH
c/o IOS Press, Inc.
6751 Tepper Drive, Clifton
Fax: +1 703 830 2300
Karen S. Anderson, MD, PhD
Biodesign Institute, Arizona State University, Tempe, AZ
Liming Cheng, PhD
Tongji Medical College
Sam Hanash, MD, PhD
University of Texas MD Anderson Cancer Center, Houston, TX
Kazufumi Honda, PhD
Nippon Medical School, Tokyo
Li Jiang, MD, PhD
Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
Anna Lokshin, PhD
University of Pittsburgh Cancer Institute, Pittsburgh, PA
YingYing Lu, MD, PhD
Comprehensive Liver Cancer Center
Zhen Zhang, PhD
Johns Hopkins University School of Medicine, Baltimore, MD
Lei Zheng, MD, PhD
Southern Medical University, Guangzhou
Ziding Feng, PhD
Fred Hutchinson Cancer Research Center, Seattle, WA
Steven J. Skates, PhD
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Senior Editorial Board
Timothy M. Block, PhD
Baruch S. Blumberg Institute
Roger Chammas, MD, PhD
University of São Paulo, Instituto do Câncer
Claudia Bessa P. Chaves, MD, PhD
Brazilian National Cancer Institute
Alexander Borowsky, MD
UC Davis Pathology and Laboratory Medicine
Arul M. Chinnaiyan, MD, PhD
University of Michigan
Xiaohong Han, MD
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Tony Hu, PhD
Arizona State University
Aija Linē, PhD
Latvian Biomedical Research and Study Centre
Cesar Lopez-Camarillo, PhD
Universidad Autonoma de la Ciudad de Mexico
Patrick Nasarre, PhD
Medical University of South Carolina
Norbert Nass, PhD
Brandenburg Medical School Theodor Fontane, University Hospital Brandenburg an der Havel
Cheng Peng, PhD
University of Queensland
Wenxin Qin, PhD
Shanghai Cancer Institute
Karin D. Rodland, PhD
Cell, Developmental, and Cancer Biology, Oregon Health & Science University
John Semmes, PhD
Eastern Virginia Medical School
Yoganand Balagurunathan, PhD
H. Lee Moffitt Cancer Center
Wei-Min Chang, PhD
Taipei Medical University
Richard J. Cote, MD
Washington University in St. Louis School of Medicine
Shubham Dutta, PhD
University of Massachusetts Medical School
Amit Gupta, PhD
All India Institute of Medical Sciences
Jyoti Kode, PhD
Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre
Minetta C. Liu, MD
Tao Liu, PhD
Pacific Northwest National Laboratory
Bramanandam Manavathi, PhD
University of Hyderabad
Sarah Mazzilli, PhD
Boston University Chobanian & Avedisian School of Medicine
Robert L. Moritz, PhD
Institute for Systems Biology
Adrian O’Hara, PhD
Liverpool John Moores University
John Charles Rotondo, PhD
Department of Medical Sciences, University of Ferrara
Matthew B. Schabath, PhD
H. Lee Moffitt Cancer Center & Research Institute
David Sidransky, MD
Johns Hopkins University
Amit Singal, MD, MS
University of Texas Southwestern Medical Center
Sanford Stass, MD
University of Maryland School of Medicine
Sebastien Taurin, PhD
Arabian Gulf University
Bechien U. Wu, MD, MPH
Center for Pancreatic Care, Division of Gastroenterology
Kaiser Permanente Los Angeles Medical Center
Cabell's Guide or Directory
Chemical Abstracts Service (CAS)
Microsoft Academic Search
Prous Science Integrity
Ulrich's Periodicals Directory
Web of Science: Biological Abstracts
Web of Science: BIOSIS Previews
Web of Science: Journal Citation Reports/Science Edition
Web of Science: Science Citation Index Expanded (SciSearch®)
By default, articles published in Cancer Biomarkers are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library. This means that the final published version will be freely available to anyone worldwide, indefinitely, under a Creative Commons license and without the need to purchase access to the article. This is also referred to as “gold” open access.
Gold open access pricing
Authors who choose gold open access publication will be subject to an article publication charge of €1500 / US$1500 for publication under the CC BY-NC 4.0 license or €2150 / US$2150 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. After an article is accepted for publication, the corresponding author will be informed regarding the open access option during the production stages, and will have the opportunity to purchase open access for their article. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.
Green open access
Authors who do not make use of the gold open access option may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.
Peer Review Policy
Cancer Biomarkers is a peer-reviewed journal. Articles submitted to the journal undergo a single blind peer review process. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. Please visit our reviewer guidelines for further information about how to conduct a review.
After automatic plagiarism screening through iThenticate, all submitted manuscripts are subjected to initial appraisal by the Editor-in-Chief and, if found suitable for further consideration, to rigorous peer review by independent, anonymous expert referees. Reasons to reject a paper in the pre-screening process could for example be that the work does not fall within the aims and scope, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.
Papers deemed suitable to be reviewed will be assigned to a handling editor. The handling editor will then invite reviewers to comment on the work. They might consider inviting the reviewers suggested by the author or not. Editors and reviewers are asked to excuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s).
As a standard policy, decisions are based on three reviews, in some specific circumstances a minimum of two reviews may be deemed sufficient to make a decision on a paper. The Editor-in-Chief strives to ensure a typical turnaround time of 3 months.
Reviewers are asked to judge a paper on at least:
- Significance to field
- Relevance to journal
- Data analysis
- Literature review
- Writing style/clarity
Based on the received reviews the handling editor will propose to the Editor-in-Chief a recommendation:
- Minor revisions required
- Major revisions required
They mean the following:
- The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.
- The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors have been addressed satisfactorily. The revised manuscript will be examined by the Editor in Chief and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.
- The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.
Authors are notified by the Editor-in-Chief, whose decision is final.
Call for Papers Announcement (Aug 2022) – A special issue is planned on “Single-Cell Proteomics Workflow for Cancer Research” (Guest Editor: Tao Liu, PhD) to showcase perspectives or research on state-of-the-art single-cell proteomics methods, platforms, computational tools, and relevant applications in cancer. Discover more here! (deadline for submission: Aug 1, 2023)
Special Issue Published – The latest special issue in Vol.33, Iss.4 (Apr 2022), on the topic "Collaboration Between US and Japan for the Early Detection of Cancer" (guest editor: Kazufumi Honda), is openly available until Oct 31, 2022. Read the issue newsletter here!
Presentation at IOS Press Symposium – The journal's Editor-in-Chief Sudhir Srivastava was one of the esteemed scholars who participated in the IOS Press 35th anniversary symposium on Mar 31, 2022 in Amsterdam. The focus of his presentation was the journal's history, current developments, and prospects, as well as more broadly the area of biomarkers research. Discover more here!
AI Special Issue – Discover this special issue on the topic "Applications of Artificial Intelligence in Biomarker Research" (guest editor: Karin Rodland, PhD) in Vol.33, Iss.2 (Feb 2022), which was openly available until Aug 31, 2022. View background and testimonials here!
Journal Impact Factor – The latest Journal Citation Reports sees CBM's Impact Factor changing to 3.828 (Source Clarivate, 2022). The journal is listed in the Oncology category of Science Citation Index Expanded (SCIE).
Discover the contents of the latest journal issue:
Prediction for recurrent non-muscle invasive bladder cancer
Aravind Raveendran, Keqiang Li, Guoqing Xie, Yu Zhang, Haofan Wu, Zhenlin Huang, Zhankui Jia, Jinjian Yang
Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis
Patrick Nasarre, Julie B. Siegel, Lillian Hsu, Rupak Mukherjee, Meghan Gormley, Bailey Richardson, Imran Khan, Jordan E. Morningstar, Eleanor Hilliard, John P. O’Bryan, Kristi L. Helke, Laura Spruill, Nathan G. Dolloff, Nancy Klauber-DeMore
Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice
Daniele Lorenzini, Andrea Vingiani, Elena Conca, Chiara Costanza Volpi, Desirè Viola Trupia, Annunziata Gloghini, Federica Perrone, Elena Tamborini, Gian Paolo Dagrada, Luca Agnelli, Iolanda Capone, Adele Busico, Giancarlo Pruneri
Increased expression of LINC00323 correlates with tumor progression and poor prognosis of gastric cancer
Jin-Jie Li, Si-Yu Zhu, Qin Lu, Chao Yang, Lei Ma, Chuan Jin, Shu-Zhong Cui, Ji-Ding Fu, Li-Si Zeng, Xian-Zi Yang
Salidroside suppresses proliferation and migration in prostate cancer via the PI3K/AKT pathway
Teng-Fei Ma, Ru-Han Liu, Qin Yang, Wen-Chang Xiao, Lu Yin, Miao Yin, Jin-Song Zhang, Chi-Hua Wang